Erratum: A potential role for the inhibition of PI3K signaling in glioblastoma therapy (PLoS ONE 10:6 (e0131670) DOI 10.1371/journal.pone.0131670);A potential role for the inhibition of PI3K signaling in Glioblastoma therapy

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Ströbele, Stephanie ^a   Schneider, Matthias ^a   Schneele, Lukas ^a   Siegelin, Markus D ^b   Nonnenmacher, Lisa ^a   Zhou, Shaoxia ^a   Karpel Massle, Georg ^a,b   Westhoff, Mike Andrew ^a   Halatsch, Marc Eric ^a   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; FURAN DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL COUNT; CELL DIFFERENTIATION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PHARMACOLOGICAL BLOCKING; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CANCER STAGING; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; DRUG SYNERGISM; FURANS; GLIOBLASTOMA; HUMANS; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84938717511     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134770     Document Type: Erratum

References (60)

1. Johnson DR, O'Neill BP (2011) Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107: 359-364. doi: 10.1007/s11060-011-0749-4 PMID: 22045118
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. PMID: 15758009
3. Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331. doi: 10.1038/nrc2818 PMID: 20414201
4. Giese A (2003) Glioma invasion - pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumorsuppressor p53 and protooncogene ETS-1. Acta Neurochir Suppl 88: 153-162. PMID: 14531573
5. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al. (2011) Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20: 810-817. doi: 10.1016/j.ccr.2011.11.005 PMID: 22137795
6. Ene CI, Fine HA (2011) Many tumors in one: a daunting therapeutic prospect. Cancer Cell 20: 695-697. doi: 10.1016/j.ccr.2011.11.018 PMID: 22172718
7. Westhoff MA, Bruhl O, Nonnenmacher L, Karpel-Massler G, Debatin KM (2014) Killing me softly-future challenges in apoptosis research. Int J Mol Sci 15: 3746-3767. doi: 10.3390/ijms15033746 PMID: 24595238
8. Network TCGAR (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068. doi: 10.1038/nature07385 PMID: 18772890
9. Fan QW, Weiss WA (2010) Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 347: 279-296. doi: 10.1007/82-2010-67 PMID: 20535652
10. rd (2013) Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 71: 829-842. doi: 10.1007/s00280-012-2043-3 PMID: 23377372
11. Cloughesy TF, Cavenee WK, Mischel PS (2013) Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 9: 1-25. doi: 10.1146/annurev-pathol-011110-130324 PMID: 23937436
12. Mendiburu-Elicabe M, Gil-Ranedo J, Izquierdo M (2014) Efficacy of rapamycin against glioblastoma cancer stem cells. Clin Transl Oncol 16: 495-502. doi: 10.1007/s12094-013-1109-y PMID: 24043497
13. Akhavan D, Cloughesy TF, Mischel PS (2010) mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12: 882-889. doi: 10.1093/neuonc/noq052 PMID: 20472883
14. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S (2008) Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 68: 6271-6280. doi: 10.1158/0008-5472.CAN-07-6769 PMID: 18676851
15. Westhoff MA, Kandenwein JA, Karl S, Vellanki SH, Braun V, Eramo A, et al. (2009) The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene 28: 3586-3596. doi: 10.1038/onc.2009.215 PMID: 19633683
16. Westhoff MA, Faham N, Marx D, Nonnenmacher L, Jennewein C, Enzenmuller S, et al. (2013) Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma. PLoS One 8: e83128. doi: 10.1371/journal.pone.0083128 PMID: 24391739
17. Enzenmuller S, Gonzalez P, Karpel-Massler G, Debatin KM, Fulda S (2012) GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. Cancer Lett.
18. Kuger S, Graus D, Brendtke R, Gunther N, Katzer A, Lutyj P, et al. (2013) Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule. Transl Oncol 6: 169-179. PMID: 23544169
19. Gil del Alcazar CR, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, et al. (2014) Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res 20: 1235-1248. doi: 10.1158/1078-0432.CCR-13-1607 PMID: 24366691
20. Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, et al. (2014) Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 14: 17. doi: 10.1186/1471-2407-14-17 PMID: 24418474
21. Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, et al. (2015) RIST: A potent new combination therapy for glioblastoma. Int J Cancer 136: E173-187. doi: 10.1002/ijc.29138 PMID: 25123598
22. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, Van Noorden CJ, et al. (2008) The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27: 2091-2096. PMID: 17934519
23. Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Nonnenmacher L, Wirtz CR, et al. (2014) Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines. Anticancer Agents Med Chem 14: 313-318. PMID: 24506460
24. Westhoff MA, Zhou S, Bachem MG, Debatin KM, Fulda S (2008) Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene 27: 5169-5181. doi: 10.1038/onc.2008.148 PMID: 18469856
25. Westhoff MA, Serrels B, Fincham VJ, Frame MC, Carragher NO (2004) SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol 24: 8113-8133. PMID: 15340073
26. Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, et al. (2008) PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.Leukemia 22: 1698-1706. doi: 10.1038/leu.2008.144 PMID: 18548104
27. Zou ZQ, Zhang XH, Wang F, Shen QJ, Xu J, Zhang LN, et al. (2009) A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. Int J Mol Med 24: 97-101. PMID: 19513541
28. Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K (2011) A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 71: 154-163. doi: 10.1158/0008-5472.CAN-10-1601 PMID: 21084267
29. Tisdale MJ (1985) Antitumour imidazotetrazines - XI: Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism. Br J Cancer 52: 789-792. PMID: 3864485
30. Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33: 245-259. PMID: 9342501
31. Johannessen TC, Bjerkvig R, Tysnes BB (2008) DNA repair and cancer stem-like cells - potential partners in glioma drug resistance? Cancer Treat Rev 34: 558-567. doi: 10.1016/j.ctrv.2008.03.125 PMID: 18501520
32. Lefranc F, Rynkowski M, DeWitte O, Kiss R (2009) Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg 34: 3-35. PMID: 19368079
33. See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO (2012) Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res 72: 3350-3359. doi: 10.1158/0008-5472.CAN-12-0334 PMID: 22573716
34. Cong ZX, Wang HD, Wang JW, Zhou Y, Pan H, Zhang DD, et al. (2013) ERK and PI3K signaling cascades induce Nrf2 activation and regulate cell viability partly through Nrf2 in human glioblastoma cells. Oncol Rep 30: 715-722. doi: 10.3892/or.2013.2485 PMID: 23708697
35. Liu Z, Jiang Z, Huang J, Huang S, Li Y, Yu S, et al. (2014) miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways. Int J Oncol 44: 1571-1580. doi: 10.3892/ijo.2014.2322 PMID: 24603851
36. Yao Y, Xue Y, Ma J, Shang C, Wang P, Liu L, et al. (2014) MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways. PLoS One 9: e95060. doi: 10.1371/journal.pone.0095060 PMID: 24736727
37. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, et al. (2006) Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther 5: 645-654. PMID: 16546979
38. Evans C, Cook SJ, Coleman MP, Gilley J (2013) MEK inhibitor U0126 reverses protection of axons from Wallerian degeneration independently of MEK-ERK signaling. PLoS One 8: e76505. doi: 10.1371/journal.pone.0076505 PMID: 24124570
39. Chen D, Zuo D, Luan C, Liu M, Na M, Ran L, et al. (2014) Glioma cell proliferation controlled by ERK activity-dependent surface expression of PDGFRA. PLoS One 9: e87281. doi: 10.1371/journal.pone.0087281 PMID: 24489888
40. Carragher NO, Westhoff MA, Fincham VJ, Schaller MD, Frame MC (2003) A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src. Curr Biol 13: 1442-1450. PMID: 12932330
41. Sunayama J, Sato A, Matsuda K, Tachibana K, Watanabe E, Seino S, et al. (2011) FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells 29: 1327-1337. doi: 10.1002/stem.696 PMID: 21793107
42. Gont A, Hanson JE, Lavictoire SJ, Parolin DA, Daneshmand M, Restall IJ, et al. (2013) PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1. Oncotarget 4: 1266-1279. PMID: 23907540
43. Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21: 283-296. doi: 10.1016/j.ccr.2012.03.003 PMID: 22439924
44. Kyurkchiev D, Naydenov E, Tumangelova-Yuzeir K, Ivanova-Todorova E, Belemezova K, Bochev I, et al. (2014) Cells isolated from human glioblastoma multiforme express progesterone-induced blocking factor (PIBF). Cell Mol Neurobiol 34: 479-489. doi: 10.1007/s10571-014-0031-3 PMID: 24474429
45. Gilbert CA, Ross AH (2009) Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem 108: 1031-1038. doi: 10.1002/jcb.22350 PMID: 19760641
46. Stupp R, Hegi ME (2007) Targeting brain-tumor stem cells. Nat Biotechnol 25: 193-194. PMID: 17287755
47. Mitchison TJ (2012) The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 23: 1-6. doi: 10.1091/mbc.E10-04-0335 PMID: 22210845
48. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A (2006) Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 132: 503-511 PMID: 16412023
49. Li A, Walling J, Kotliarov Y, Center A, Steed ME, Ahn SJ, et al. (2008) Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6: 21-30. doi: 10.1158/1541-7786.MCR-07-0280 PMID: 18184972
50. Vogel TW, Zhuang Z, Li J, Okamoto H, Furuta M, Lee YS, et al. (2005) Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res 11: 3624-3632 PMID: 15897557
51. Rixe O, Fojo T (2007) Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res 13: 7280-7287. PMID: 18094408
52. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, et al. (2006) Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66: 8139-8146. PMID: 16912192
53. Zhu Y, Shah K (2014) Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. Cancer Biol Ther 15: 815-822. doi: 10.4161/cbt.28585 PMID: 24658109
54. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, et al. (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9: 469-479. PMID: 10416987
55. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB (2001) Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 90: 105-156. PMID: 11578655
56. Wang MH, Lin CL, Zhang JJ, Weng ZP, Hu T, Xie Q, et al. (2013) Role of PTEN in cholera toxin-induced SWO38 glioma cell differentiation. Mol Med Rep 7: 1912-1918. doi: 10.3892/mmr.2013.1434 PMID: 23595342
57. Li Y, Lu HM, Li G, Yan GM (2010) Glycogen synthase kinase-3beta regulates astrocytic differentiation of U87-MG human glioblastoma cells. Acta Pharmacol Sin 31: 355-360. doi: 10.1038/aps.2010.10 PMID: 20154711
58. Sunayama J, Sato A, Matsuda K, Tachibana K, Suzuki K, Narita Y, et al. (2010) Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 12: 1205-1219. doi: 10.1093/neuonc/noq103 PMID: 20861085
59. Westhoff M-A, Karpel-Massler G, Bruhl O, Enzenmuller S, La Ferla-Bruhl K, Siegelin M, et al. (2014) A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. Molecular and Cellular Therapies 2: 32. doi: 10.1186/2052-8426-2-32 PMID: 26056598
60. Kil WJ, Tofilon PJ, Camphausen K (2012) Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol 7: 25. doi: 10.1186/1748-717X-7-25 PMID: 22356893